Propanc Biopharma, Inc. (PPCB) stock
PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
$1.94+0.02 (+1.09%)
Close on Nov 13, 2026Market cap $12.29MP/E –Yield –
Propanc Biopharma total assets
Total assets on the balance sheet at the end of each period.
Propanc Biopharma's total assets was $10.33M at Sep 30, 2026. For fiscal 2026 it was $12.78M, down 34.9% from the year before. Over ten years it grew 42.2% a year on average. The highest annual figure on record is $19.63M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $12.78M | -34.9% |
| FY2025 | Jun 30, 2025 | $19.63M | +27028.9% |
| FY2024 | Jun 30, 2024 | $72.37K | +20.0% |
| FY2023 | Jun 30, 2023 | $60.33K | -26.1% |
| FY2022 | Jun 30, 2022 | $81.65K | +523.2% |
| FY2021 | Jun 30, 2021 | $13.10K | -86.7% |
| FY2020 | Jun 30, 2020 | $98.52K | -3.1% |
| FY2019 | Jun 30, 2019 | $101.65K | +42.4% |
| FY2018 | Jun 30, 2018 | $71.39K | -24.9% |
| FY2017 | Jun 30, 2017 | $95.07K | -74.9% |
| FY2016 | Jun 30, 2016 | $379.14K | -39.5% |
| FY2015 | Jun 30, 2015 | $627.07K | +451.3% |
| FY2014 | Jun 30, 2014 | $113.75K | +6410.9% |
| FY2013 | Jun 30, 2013 | $1.75K | -96.2% |
| FY2012 | Jun 30, 2012 | $46.27K | -99.6% |
| FY2011 | Jun 30, 2011 | $10.81M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $10.33M | -42.6% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $12.78M | -34.9% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $14.33M | -36.4% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $15.11M | +19142.3% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $17.98M | +28144.1% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $19.63M | +27028.9% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $22.53M | +60235.2% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $78.53K | -67.5% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $63.64K | -64.7% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $72.37K | +20.0% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $37.34K | -74.0% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $241.91K | +123.9% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $180.37K | +91.4% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $60.33K | -26.1% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $143.74K | -15.2% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $108.02K | -2.0% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $94.25K | +51.6% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $81.65K | +523.2% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $169.46K | +504.3% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $110.18K | +171.3% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $62.17K | -19.8% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $13.10K | -86.7% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $28.04K | -56.1% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $40.62K | -37.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $77.55K | -60.8% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $98.52K | -3.1% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $63.94K | -75.4% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $65.43K | -90.8% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $197.66K | +138.8% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $101.65K | +42.4% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $259.92K | +134.7% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $712.60K | +452.1% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $82.78K | -49.1% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $71.39K | -24.9% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $110.75K | +147.3% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $129.08K | -5.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $162.51K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $95.07K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $44.79K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $135.84K | – |
See a number that looks wrong?